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After HCV infection, the association between the humoral response and viral sequence evolution remains
unclear. We investigated the mechanisms leading to early HCV clearance and spontaneous recovery in
two patients. The early evolution of the HCV envelope glycoproteins, and the infectivity spectrum of
variants were explored using retroviral pseudoparticles bearing HCV envelopes. Ability of the autologous
neutralizing response to control these variants was analyzed.
For the ﬁrst case, the maximum neutralizing activity was for serum collected between two and three
months post ALT peak, this activity was still detectable after 30 months. For the second case, autologous
neutralizing activity against the variant isolated at the ALT peak was detected in every serum collected
between 4 days and 13 months after. The neutralizing response was sustained beyond the time at which
the virus was cleared. This raise interesting questions about the role of such antibodies in case of
re-exposure.
& 2013 Elsevier Inc. All rights reserved.Introduction
It is estimated that worldwide, 150 to 200 million people are
infected by hepatitis C virus (HCV). HCV is a major cause of chronic
hepatitis, cirrhosis and hepatocellular carcinoma (Alter, 2007).
HCV belongs to the Hepacivirus genus of the Flaviviridae family
(Robertson et al., 1998). HCV is genetically highly diverse. To date,
six major HCV genotypes have been described, with a large
number of subtypes per genotype (Kuiken and Simmonds, 2009;
Simmonds et al., 2005). The high replication rate together with the
absence of any proofreading function of the viral RNA-dependent
RNA polymerase is responsible for the large intra-patient genetic
variability of HCV (Bukh et al., 1995). Accordingly, the extent of
viral diversiﬁcation of HCV strains within a single HCV-positive
individual increases signiﬁcantly with time, resulting in the
development of HCV quasispecies (Farci and Purcell, 2000). The
continuous emergence of viral variants in the host is one of the
mechanisms explaining the escape of HCV from immune survey.
The glycosylated envelop proteins E1 and E2 are exposed at the
surface of the viral particle, and are subjected to high rates ofll rights reserved.
rs.fr (C. Gaudy-Grafﬁn).mutation (Ray et al., 1999). They play an essential role in viral
entry and are major targets for neutralizing antibodies (Di Lorenzo
et al., 2011; Edwards et al., 2012; Zeisel et al., 2007).
After initial exposure to HCV, only 30% of infected individuals
recover spontaneously. Both host and viral factors determine the
natural course and outcome of HCV infection. High genetic
diversity of the hypervariable region-1 of E2 has been reported
to be correlated with chronic carriage (Farci et al., 2000), but
contradictory results have also been published (Weseslindtner
et al., 2009).
The role of the neutralizing antibody response in pathogenesis
and viral clearance is poorly understood, and the association
between the humoral response and viral sequence evolution
remains unclear. The development of the HCV pseudoparticles
(HCVpp) model (Bartosch et al., 2003; Flint et al., 2004; Hsu et al.,
2003) has made it possible to investigate neutralizing antibodies
associated with HCV infection. Heterologous HCVpp have been
used to explore humoral immunity during HCV natural infection;
but the ﬁndings are controversial: neutralizing antibodies were
found both during acute and chronic infection (Logvinoff et al.,
2004; Netski et al., 2005).
A few studies have also used autologous HCVpp to explore the
neutralizing antibody response during clearance and/or carriage of
HCV type 1 (Dowd et al., 2009; Lavillette et al., 2005; Pestka et al.,
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investigated the mechanisms leading to early HCV clearance and
spontaneous recovery in two patients in whom HCV was eradi-
cated. The purpose of this work was: (i) to explore the diversity
and the early genetic evolution of the HCV envelope glycoproteins
E1 and E2, and the infectivity spectrum of isolated variants and (ii)
to analyze the ability of the autologous neutralizing response to
control these variants and thus HCV infection.Results
Genetic diversity of E1 and E2 sequences
The segment encoding E1 and E2 (2036 nucleotides) was
successfully ampliﬁed from one sample (P1t2) collected from the
ﬁrst patient (P1), 17 days after the ALT peak. Thirty-three clones
were successfully sequenced; the average diversity was 0.0026/bp.
Five clones corresponded to a major variant (P1t2c16). A minor
variant (P1t2c28, 1/33) bore two substitutions relative to the major
variant, including one at position 645 corresponding to the E2-N11
glycosylated site.
The segment encoding E1 and E2 (1748 nucleotides) was
successfully ampliﬁed from two samples (P2t1 and P2t2) collected
from the second patient at the time of the ALT peak and 17 days
later. Forty-one P2t1 clones and 39 P2t2 clones were sequenced.
The average diversity was 0.0086/bp. In P2t1, 10 of the 41 clones
corresponded to a major variant (P2t1c43). P2t2 included two
major variants – P2t2c6 (6/39) and P2t2c34 (7/39) – with four and
ﬁve mutations, respectively, relative to the major t1 variant
(positions 170, 258, 260, 303 and 522). Two out of the 41 clones
(5%) in P2t1 were identical to the major P2t2c6 variant. The P2
genetic variation was structured between the two time samples
with a highly signiﬁcant genetic differentiation (FST¼0.65
po0.001) indicating signiﬁcant evolution in the meantime. Simi-
larly, the ML evolutionary tree presents a subtree of subset t2
signiﬁcantly separated from subset t1 (bootstrap support index of
the subtree: 82%; Fig. 1).
For patient P1, ﬁve potential N-glycosylated sites were identi-
ﬁed in E1 at positions 196 (N1), 209 (N2), 234 (N3), 250 and 305
(N4) for all 33 clones. In E2, ten N-glycosylated sites were
identiﬁed for the 33 clones at positions 417 (N1), 423 (N2), 430
(N3), 448 (N4), 532 (N6), 540 (N7), 556 (N8), 576 (N9), 623 (N10)
and 645 (N11). The N645S substitution in P1t2c28 abolishes the site
N11 whereas substitution T647A in P1t2c36 impeded prediction of
an effective glycosylation. For patient P2, four N-glycosylated sites
were identiﬁed in E1 at positions 196 (N1), 209 (N2), 234 (N3) and
305 (N4) for all 80 clones. In E2, 10 N-glycosylated sites were
predicted for 79 clones at positions 417 (N1), 423 (N2), 430 (N3),Fig. 1. Maximum-likelihood phylogenetic distribution of variants identiﬁed at
t1 and t2 in patient 2. The ML evolutionary tree was computed with PHYML and
the HKY85 best ﬁt mutational model. Open circles: t1; dark circles: t2. The
bootstrap support index (randomization test) of t2 subtree is indicated.448 (N4), 476 (N5), 532 (N6), 556 (N8), 576 (N9), 623 (N10) and
645 (N11). The N-glycosylation site N2 was not predicted for the
variant P2t2c37 (T424A), N6 was not predicted for P2t1c40 and
P2t1c27 (T534A) and N9 was not predicted for P2t1c10 (S581P).
Selective pressure in E1 and E2 of patient 2
The Mc Donald Kreitman test comparing the ratios of non
synonymous to synonymous changes at times t1 and t2 (t1: 42/40;
t2: 49/20) versus that of ﬁxed differences with the outgroup (og)
lineage (t1 vs. og: 47/78; t2 vs. og: 56/96) showed an excess of
non-synonymous within-sample replacements suggesting on
average, slightly deleterious mutations from marginal for t1
(p¼0.06), to more drastic for t2 (po0.001). A highly signiﬁcant
negative correlation (p¼0.009) was found between linkage dis-
equilibrium and the distance between mutations thereby strongly
suggesting the presence of recombination (Suppl. Fig. S1). The Rm
approach identiﬁed nine putative recombination or multiple
mutation hit events and the dataset was partitioned accordingly
before the selective analyses. Negative selection detection was
assessed with the FEL procedure (Fig. 2). Six sites were found to be
negatively selected at positions 384 (po0.05), 268, 482, 496, 529
and 730 (po0.1). The related and opposite direction MEME
approach showed one site with strong evidence for positive
selection and located in E2-HVR3 (aa 459; po104). Table 1
Infectivity of HCVpp harboring selected E1 and E2 proteins
HCVpp were produced with representative E1 and E2
sequences to explore the consequences of mutations on infectivity
and neutralization. The selection of natural variants is shown in
Table 2. We also produced two mutants (P1t2c16-M299V and
-N645S) derived from the major variant P1t2c16 but carrying
substitutions found in P1t2c28. We selected the major variants
of the quasispecies for P2t1 and P2t2: P2t1c43 (10/41), P2t2c6 (6/
39) and P2t2c34 (7/39). Other minor variants, bearing single
mutations, were selected.
The composition of the pseudoparticles was analyzed with a
panel of monoclonal antibodies. The MLV capsid was detected by
western blotting in every preparation, including the three controls
(HCVpp-1a, dEnv and Ampho) (Figs. 3 and 4B).
The E1 and E2 proteins were detected by Mab H111 and 3/11 in
HCVpp from the four variants isolated from patient P1 (Fig. 3B,
lanes 1–4). The absence of the N11 glycosylation site from P1t2c28
and p1t2c16 N645S shifted the E2 bands (Fig. 3B, lanes 2 and 4).
Mab H111 did not recognize the HCVpp-1a control, presumably
due to the divergent sequence of the epitope (Fig. 3B, lane 7), but
the presence of E1 in these pseudoparticles was conﬁrmed with
another Mab: A4 (Fig. 3B, lane 7′).
E1 was not detected in HCVpp carrying the envelop variants
isolated from patient P2 with either monoclonal used for exploring
patient P1. The corresponding sequence of the type 3 envelopes in
P2 isolates differed substantially from the epitope recognized by
Mab H-111 (5 differences out if 11 aa) and A4 (3 differences out of
11 aa). Mab 3/11 recognized E2 in 10 of the 11 HCVpp preparations
(Fig. 4B). For P2t2c37, a T424A mutation in the Mab 3/11 epitope
prevented E2 detection by western blotting.
For patient P1, pseudoparticles bearing the envelope of the
major variant, P1t2c16-HCVpp, were the most infective in Huh7
(Fig. 3A). The P1t2c28 HCVpps in which envelope had mutation
N645S at the N11 glycosylation site had half the infectivity of the
major variant, and P1t2c16N645S, a recombinant envelop bearing
the same mutation was similarly (2.5 fold) less infective. The
M299V substitution in E1 did not alter the infectivity.
For patient P2, at t1, the highest level of infectivity in Huh7
cultures was observed for HCVpp bearing the envelope of the
Fig. 2. Detection of E1 and E2 amino acid sites under selection in patient 2. For each site (x axis), a χ2 test (y axis) investigates if the non-synonymous mutation rate is
different from the synonymous one (red bins). Top part: The MEME algorithm detects one highly signiﬁcant codon under episodic diversifying selection (nnnn¼po10-4).
Bottom part: The FEL negative selection test detects six sites under purifying negative selection shownwith a tilde (po0.1) or a star n (po0.05). Note that the y axis is then
oriented in the opposite direction: positive χ2 values. Codons are numbered taking H77 strain as reference. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
Table 1
Biochemical and virological characteristics of patients P1 and P2.
Serum ALTa Time
Anti-HCV
HCV RNA Genotype e
denomination (IU/ml) since ALT peak EIA b
Immunoblot c
PCR d
Anti-core Anti-NS3 Anti-NS4 Anti-NS5
NA 5 mo before –
P1t0 (NA) 1998 NA
P1t1 625 10 dy 44 – +++ ++ – + 1b
P1t2 1076 17 dy – ++++ +++ ++ +
P1t3 53 54 dy – ++++ ++++ ++ –
P1t4 32 3 mo – ++++ ++++ ++ –
P1t5 68 10 mo – ++++ +++ – –
P1t6 116 30 mo – +++ ++ – –
P1t7 67 38 mo – +++ ++ – –
NA 22 mo before –
P2t0 (NA) 1089 — +
P2t1 1699 — ++ + – – + 3
P2t2 162 17 dy + ++ – –
P2t3 67 48 dy ++++ ++++ +++ – +
P2t4 65 83 dy ++++ ++++ ++++ – –
P2t5 23 5 mo NA NA NA NA –
P2t6 11 6 mo ++++ ++++ +++ – –
P2t7 NA 11 mo ++++ ++++ – – –
P2t8 24 13 mo ++++ ++++ – – –
P2t2: This sample was not tested for HCV RNA with a commercial assay. P2t3: HCV load was undetectable (o620 UI/ml) using the Bayer Versant HCV RNA 3.0 but HCV RNA
was detected using Amplicor HCV detection kit 2.0.
NA: Not available; dy: days; mo: months.
a Normal ALT valueo35 IU/ml.
b HCV 3.0 ELISA test system (Ortho-Clinical Diagnostics, Johnson and Johnson).
c RIBA HCV 3.0 (Chiron corporation). Intensity of the reactions is based on criteria provided by the manufacturer and is indicated as follows: ++++, very strongly positive;
+++, strongly positive; ++, moderately positive; +, weakly positive.
d Amplicor HCV detection kit 2.0 (Roche Diagnostics).
e Versant HCV genotype assay 1.0 LiPA (Bayer).
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minor E2 variants (c25, c29, c40, c47) ranged from 6 to 33 fold
lower. The amounts E2 protein incorporated into c25, 40 and c43
were relatively low as assessed by Western blotting. By contrast,c47 had the lowest infectivity (32.6 fold less than P2t1c43) despite
the highest E2 incorporation.
At t2, one (P2t2c6) of the two prevalent variants had the
highest infectivity although it was signiﬁcantly lower (4.6 fold)
Table 2
E1 and E2 variants used for the production of retroviral pseudoparticles.
Clones Frequency C E1 E2
170 258 260 299 303 309 425a 496 522b 534c 635 645d
P1 P1t2c16 5/33 P I R M D P T V S T R N
P1t2c16M229V . . . V . . . . . . . .
P1t2c16N645S . . . . . . . . . . . S
P1t2c28 1/33 . . . V . . . . . . . S
P2 P2t1c43 10/41 P V R Q T P T L K T Se R N
P2t1c25 1/41 . . . . . . . . R . . . .
P2t1c47 1/41 . . . A . . . . . . . .
P2t1c40 1/41 . I S . . . . . . A . . .
P2t1c29 3/41 . I S . A . . . . . . . .
P2t2c6 6/39 . I S . A . . . R . . . .
P2t2c34 7/39 S I S . A . . . R . . . .
P2t2c37 1/39 . I S . A . A . R . . G .
P2t2c16 1/39 S I S . A . . P R . . . .
P2t2c10 1/39 S I S R A . . . R . P . .
Positions on HCV genome are numbered using strain H77 as the reference. The frequency of each variant (the proportion of all isolates) is indicated. Major variants are
indicated in bold. Differences in amino acid sequence are shown relative to the major variant P1t2c16. Variants generated by site-directed mutagenesis are underlined.
Identities are indicated with dots.
a Amino-acid 425: Glycosylation site E2N2, in one E2 area of fusion (417–433).
b Amino-acid 522: Located in the binding domain of CD81.
c Amino-acid 534: Glycosylation site E2N6.
d Amino-acid 645: Glycosylation site E2N11.
e Corresponding to amino-acid 583 in the intergenotypic region (IgVR) in the reference strain genotype 3a D28917.
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in P2t2c34 was associated with a 53-times lower infectivity than
that of P2t2c6 and was also associated with undetectable infectiv-
ity in P2t2c10 and P2t2c37. By contrast, P2t2c16 that had abundant
E2 was not infectious in Huh7. As this variant has only one
additional mutation in comparison to infectious variants (P2t2c6
and P2t2c4), the absence of proper E2 folding should be one
hypothesis.
Autologous neutralizing response
The autologous neutralizing activity of serum from P1 was
investigated in Huh7 using HCVpp from P1t2c16, the major HCV
variant, and from P1t2c28, a variant bearing the N645S mutation
leading to the loss of the E2-N11 glycosylation site. Serum
collected 17 days after the ALT peak neutralized P1t2c16 entry;
the maximum neutralizing activity was for serum collected
between two and three months post ALT peak, and the activity
was still detectable in serum collected 30 but not 38 months after
the ALT peak (Fig. 5A). Neutralizing activity towards the minor
variant was detected between 2 and 30 months post ALT, but was
ﬂuctuating (Fig. 5b).
For P2, autologous neutralizing activity in Huh7 cells against
HCVpp pseudotyped with the major variant isolated at t1
(P2t1c43) was detected in every serum collected between 4 days
and 13 months after the ALT peak. Further titration experiments
showed a gradual increase of neutralization activity over time with
a maximum 5 to 6 months after the ALT peak (Fig. 6). We used
P2t2c6, the major variant, to study autologous neutralizing activity
found at t2. A neutralizing response was detected only in the
serum collected 3 months after the ALT peak.Discussion
Understanding the evolution of HCV in the early weeks of an
infection and the dynamic of viral variation versus efﬁcacy of host
response is essential in order to develop speciﬁc immunotherapy
and vaccine. Neutralizing antibodies directed to the envelopeglycoproteins have a major role in this interplay. Due to the high
heterogeneity of HCV envelope proteins, the use of heterologous
E1 and E2 in neutralization assays may be misleading. For
instance, neutralization assays with the prototype strain H77 have
been shown to be less sensitive than those with autologous
HCVpp: the sensitivity decreases as the chosen E1 and E2
sequences diverge from H77 (Dowd et al., 2009). Sequential
autologous neutralization assays in a case of persistent infection
(patient H) showed that humoral response failed to neutralize
infection due to the continuous emergence of escape mutants (von
Hahn et al., 2007). The sequential autologous response has seldom
been studied in cases of resolutive hepatitis C, and even these few
analyses involved cases of very late viral clearance, occurring after
several months of infection (Dowd et al., 2009; Raghuraman et al.,
2012). In our work, we report the analysis of two cases of early
HCV clearance. To our knowledge, this is the ﬁrst study aimed at
investigating the autologous neutralizing response in the clinical
context of “early resolvers” using a collection of HCVpp bearing
autologous envelope proteins including major and minor variants
(Table 2). In these two cases, the time to clearance was clearly
documented: P1 infected by a type 1b HCV strain cleared the virus
between 17 and 54 days after the ALT peak, and P2 cleared a type
3a virus after between 48 and 83 days.
We conducted a detailed exploration of quasispecies evolution
during the very early stages of infection with HCV type 3a (P2),
involving ampliﬁcation of E1 and E2 cDNA from serum samples
collected only 17 days apart. The elevated and highly signiﬁcant
genetic differentiation ratio Fst between t1 and t2 reﬂect signiﬁ-
cant mutation frequency variation. This implies that the viral
population signiﬁcantly evolved, though not necessarily function-
ally, between the two sampling times. Similarly the separated
phylogeny of the two samples suggests a rapid turnover of
variation. As to more functional evolution, we applied selective
analyses on codons that showed some variation (synonymous and/
or non synonymous one) and could be tested for random evolu-
tion. We found evidence for purifying selection against deleterious
amino acid replacements on six codon positions. One codon
position was also detected as subjected to diversifying selection
favoring successive amino acid replacements. Direct functional
Fig. 3. Cell entry by pseudoparticles harboring HCV E1 and E2 glycoproteins
corresponding to selected variants isolated from early primoinfection in
patient 1. (A) Infectivity in Huh7 cells of HCVpp harboring four different E1E2
glycoproteins: major variant P1t2c16, lane 1, minor variant P1t2c28, lane 2, and
mutants P2t2c16M299V and P2t2c16N645V (lanes 3 and 4). Retroviral pseudoparti-
cles bearing the MLV amphotrope envelope (lane 5) or without HCV envelope
(dEnv, lane 6) were used as positive and negative controls, respectively, for entry
into Huh7 cells. The retroviral pseudoparticle named HCVpp-1a (lane 7) was used
as a positive entry control. Infectious titers were deduced from the transduction
efﬁciencies as assessed from RLU measurements. Columns are the geometric mean
of four experiments; maximum value is also indicated. (B) Expression and
incorporation of ﬁve different HCV envelope glycoproteins and MLV capsid protein
were assessed by western blotting of retroviral pseudoparticles. Anti-E1 antibody
H111 was used for lanes 1–7 and A4 for lane 7′. Anti-E2 antibody (3/11) and anti-
MLV capsid antibody were used for lanes 1–7′. MLV core was detected in all
pseudoparticles including the three controls. Using Mab H111, E1 was detected in
all HCVpp preparations except the HCVpp-1a control (lane 7) due to sequence
difference in the epitope. In this construct, E1 was detected with another Mab
named A4 (lane 7′). E2 was detected in all ﬁve HCVpp preparations (lanes 1–4
and 7).
Fig. 4. Cell entry of pseudoparticles harboring HCV E1 and E2 glycoproteins
corresponding to selected variants isolated from patient 2 during early infec-
tion. (A) Infectivity of HCVpp harboring 10 different E1 and E2 glycoproteins from
samples collected at t1 and t2: the major variants P2t1c43, P2t2c6 and P2t234; and
the minor variants P2t1c25, P2t1c29, P2t1c40, P2t1c47, P2t2c10, P2t2c16 and
P2t2c37. Retroviral pseudoparticles without envelope (dEnv) or bearing ampho-
tropic MLV envelope were used as negative and positive controls, respectively, for
entry into Huh7 cells. Infectious titers were deduced from the transduction
efﬁciencies determined from the RLU. Columns are the geometric mean of four
experiments, maximum value is also indicated. (B) Expression and incorporation of
the 11 different HCV envelope glycoproteins and MLV capsid protein were assessed
by Western blotting of retroviral pseudoparticles using monoclonal anti-E2 and
anti-MLV capsid antibodies. Mab 3/11 detected E2 protein in 10 of 11 HCVpp
preparations. For P2t2c37, a T424A mutation located in the Mab 3/11 epitope
prevented detection of E2.
L. Esteban-Riesco et al. / Virology 444 (2013) 90–9994analyses of extant variation provide evidence for phenotypic effect
of variants. In contrast, evolutionary analyses can provide indirect
and complementary functional information regarding for instance
past episode of positive selection or deleterious mutations that
were removed by selection and are thus no more directly acces-
sible. For instance, deleterious candidates correspond to codons
with a deﬁcit of amino acid replacements compared to synon-
ymous mutations. Most of them may simply not show any amino
acid replacements or they would be rare and unlikely to be
sampled. They may thus not be involved in functional analyses.
It is thus not surprising that the two types of results hardly
overlap. Yet, a deleterious candidate position 496 corresponds to
one replacement from leucine to proline on one unique variant
P2t2c16 that was lacking infectivity in Huh7. The two kinds of
approaches are thus congruent in this case.
As to genetic exchange, whatever the mechanism, it should
mostly occur between sequences in contact and thus most often
similar, making such events hard to identify on a ﬁrst sight basis or
with empirical methods. It may also involve rare events only
detectable on an evolutionary scale. It can then be mostly assessedindirectly through population genetics methods. Our evidence for
a correlation between genetic association and the distance separ-
ating mutations suffers hardly any simple alternative explanation
than recombination. This is compatible with a number of studies
providing rather direct evidence for recombination between more
distant HCV variants (Hoshino et al., 2012; Kalinina et al., 2002;
Moreno et al., 2009; Noppornpanth et al.,. 2006).
Turning to sequence examination of aminoacidic sequences,
the major variant identiﬁed at t1 for P2 (P2t1c43) was not
detected in a set of 39 clones obtained at t2 (17 days later). A
minor variant P2t1c26, representing only 5% of the quasispecies at
t1, had reached 15% at t2. This variant exhibited four mutations
relative to the major variant at t1. The second major variant at t2
(P2t2c34, 20%) had an additional mutation (Table 2). These ﬁve
mutational events were all outside HVR1. This is not the case for
late HCV clearance: Dowd and colleagues reported ﬁve, nine and
six amino acid substitutions within HVR1, at 16, 8 and 9 months,
respectively, following initial detection of viremia (Dowd et al.,
2009). Here, we found a more rapid accumulation of substitutions:
four and ﬁve in the E1 and E2 sequences occurred within a much
shorter time (17 days). Minor E2 variants at t1 (c25, c29, c47, c40)
had a lower infectivity than the major variant P2t1c43. Interest-
ingly, P2t1c25 bore a single difference (K522R) from the major
variant P2t1c43, and it mapped in the CD81 binding site, close to a
fusion determinant (aa 502–520) (Lavillette et al., 2007). Rapid
evolution was associated with the major variant at t2 being less
infective than the major variant at t1. The minor variants at t2
were also less infective (Fig. 4A). We observed a relative dissocia-
tion between the level of E2 incorporation into the various HCVpp
and the level of infectivity. This was presumably due to the nature
of the sequence differences. For instance, in the variant P2t2c16,
the mutation L496P near the CD81 binding site may abolish the
Fig. 5. Autologous neutralizing response against two early variants in patient 1. The time elapsed since the ALT peak is indicated in brackets. HCVpp infectivity was
measured after incubation with patients sera diluted at 1:50 versus negative control (NC). An anti-E2 pool was used as positive control. (A) HCVpp bearing the envelope of
the major variant (P1t2c16). (B) HCVpp bearing the envelope of one minor variant mutated at the E2N11 glycosylation site (P1t2c28).
Fig. 6. Kinetics of the autologous neutralizing response against HCVpp bearing the envelope of the major early variant isolated from patient 2. Infectivity and
neutralization of P2t1c43 HCVpp were studied in the presence of serial dilutions (1:25, 1:50, 1:100, 1:200 and 1:400) of sequential autologous sera (P2t1 to P2t8) or of a pool
of negative sera (NC). IgGt3, a pool of anti-HCV type 3 globulins, was used as a positive neutralization control. (A) The time elapsed since the ALT peak is indicated in
brackets; (n): at the time of ALT peak. Raw results of infectivity assays expressed as relative luciferase units (RLU). (B) Evaluation of the neutralizing response by comparing
infection in the presence of serum versus infection in the presence of the negative control pool NC at the same dilution.
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incorporation of E2 (Zhang et al., 2004).
For P1, we studied the distribution of variants in a single
sample taken 17 days after the peak of ALT. We observed an
unusual natural variant (P1t2c28) bearing a N645S substitution in
protein E2 that led to the loss of the N11 glycosylation site. The
E2-N11 site was maintained in the remaining 32 variants isolated
from this patient. Previous reports indicate that in vitro mutations
that inactivate this glycosylation site are detrimental to infectivity
(Helle et al., 2007,2010), and we similarly observed in vivo that the
infectivity of this variant was half that of the major variant.
Experimental substitution of asparagine for serine at position645 restored the N11 glycosylation site and increased the infectiv-
ity of the modiﬁed HCVpp implicating carbohydrates attached to
N645 or the asparagine side chain in the entry process. Falkowska
et al. (2007) suggested that the substitution of alanine for
asparagine has a major effect on the folding of E1 and E2. In our
study, the expression of E1 and E2 appeared to be unaffected by
E2-N645S (Fig. 3B). The E2-N11 glycan has been shown to have a
protective effect against neutralization, as proposed by Helle et al.
following work with strain H77. They showed that glycosylation at
N645 protects HCVpp type 1a against neutralization by homolo-
gous antibodies or anti-E2 Mabs and also reduces access of CD81
to its E2 binding site. By contrast, the absence of glycosylation at
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In our work, P1t2c28 lacking E2N11 glycan was sensitive to 4 out
of 6 autologous sera. But, the major variant P1t2C16 was also
sensitive to autologous neutralization, despite having this glyco-
sylated site. The role of E2N11 glycan in HCV immune escape
needs to be conﬁrmed in future studies.
Few studies provide evidence that spontaneous and early
clearance of HCV is associated with a vigorous neutralizing anti-
body response. In the work by Dowd et al. (2009), autologous
neutralizing antibodies were either absent, or present at only very
low titer, throughout the early acute infection phase in three
patients who failed to clear HCV. By contrast, in three cases of late
spontaneous clearance, the autologous neutralizing response
against earlier variants was strong, especially at the time of
clearance. In our study, autologous neutralization was stronger in
patient P1 at the time of clearance: between 17 and 54 days after
peak ALT activity. For patient P2, the major variant found at the
ALT peak (P2t1c43) was totally absent 17 days later. Interestingly,
the corresponding neutralizing response was already detect-
able (450%) at this very early stage (t1), suggesting that auto-
logous antibodies were involved in the clearance of this major
circulating variant. Autologous neutralizing antibodies against
variant P2t2c6 were undetectable at this early stage, but were
detectable 83 days post ALT peak. This initial absence of auto-
logous neutralizing activity against P2t2c6 presumably allowed its
emergence, even though it was a very minor clone at t1 (two out
of 41 isolates, data not shown). Spontaneous HCV clearance was
observed between 48 and 83 days post ALT peak, together with
the development of a broad autologous neutralizing response
(percentage of neutralization over 80% at 83 days). In a recent
work, Raghuraman et al. (2012) also described the appearance of
autologous neutralizing antibodies followed by viral eradication,
but in a case of late clearance i.e. after 65 weeks.
Overall, we observed rapid and spontaneous clearance of HCV
infection in our two patients. This was associated with a few
selected sites and a substantial evolution of the E1 and E2 proteins
including functional one, corresponding to a loss of infectivity of
the population of variants present early after infection. Inciden-
tally, we provided indirect evidence for recombination between
closely related sequences. In addition, we clearly document the
rapid development of an autologous neutralizing response against
the major variant at the early stage of infection. We show that this
neutralizing response was sustained beyond the time at which the
virus was cleared: 3 years for patient 1, and at least 1 year for
patient 2. These observations raise interesting questions about the
role of such antibodies in the case of re-exposure. Investigation of
populations subjected to multi-exposure to HCV, such as intrave-
nous drug users, would be very informative, and help elucidate the
protective effect of HCV-neutralizing antibodies.Methods
Studied patients
We selected two patients who had developed an acute HCV
infection as indicated by seroconversion to anti-HCV. Sequential
sera were collected over 38 months for patient 1 (P1) and 13
months for patient 2 (P2) (Table 1). Samples were analyzed using a
third generation strip immunoblot assay. Completion of the proﬁle
on serial blots was considered as indicative of recent infection.
Patient 1 (P1) was an immunocompetent man, aged 60,
infected with type 1b HCV possibly through exposure from his
carrier spouse. Acute hepatitis was marked by jaundice and high
levels of serum alanine aminotransferase (ALT). Anti-HCV anti-
bodies and HCV RNA were detected ten days after the ALT peak(Table 1). Antibody reactivity against NS3, NS4 and NS5 increased
regularly over the following two months, suggesting a recent HCV
seroconversion. HCV RNA became undetectable between 17 and 54
days after the ALT peak (Table 1).
Patient 2 (P2) was an immunocompetent woman, aged 38,
contaminated by a type 3 HCV strain. Acute hepatitis was diag-
nosed because of jaundice and serum ALT levels above 1,000 UI/
mL. HCV antibodies and RNA were already detectable at that time.
The last HCV-negative serum had been collected 22 months
before. Two other ﬁndings indicated that infection had occurred
in the last months of this period. Immunoblot reactivity against
core, NS3 and NS4 peptides increased during the 3 months period
following the ALT peak. In-house anti-HCV avidity assay (Gaudy-
Grafﬁn et al., 2010), conﬁrmed that HCV seroconversion was
recent.
HCV RNA became undetectable between 2 and 3 months after
the ALT peak (Table 1).
Cells, antibodies and plasmids
Human embryo kidney cells HEK 293T; Huh7 were grown and
maintained in Dulbecco's minimal essential medium (DMF10).
Anti-E1 (H-111) monoclonal antibody (MAb) was from Dr Steven
Foung, Palo Alto, California; anti-E1 (A4) from Dr. Jean Dubuisson,
Pasteur Institute, Lille, France; anti-E2 (3/11) MAb from J. McKeat-
ing, Institute of Biomedical Research, University of Birmingham,
England, and anti- MLV capsid, a goat antibody for MLV CA p30,
from Dr JL Darlix, ENS Lyon, France.
The expression vector, pMNGag Pol, codes for the core and the
packaging components of murine leukemia virus (MLV) under the
control of the human cytomegalovirus (CMV) promoter. The
expression vector pTG-Luc MLV carries the luciferase reporter
gene under the control of the CMV promoter. A plasmid containing
the sequence coding for E1 and E2 of a type 1a HCV strain
(AAB67037: isolate H77 Hepatitis C Virus) was provided by Dr J.
Dubuisson, Pasteur Institute, Lille, France. Plasmid pCMV ampho
encodes the amphotropic MLV envelope protein.
DNA ampliﬁcation, cloning and sequencing of HCV cDNA containing
E1 and E2 domains
Viral RNA was extracted from 100 ml of serum. The Superscript
II and random hexamers (Invitrogen) were used for retrotranscrip-
tion into cDNA. A sequence encoding the C terminus of the core
protein and the full-length E1 and E2 protein domain was
ampliﬁed by nested polymerase chain reaction from 2 ml of cDNA
product using High Fidelity Platinum PCR SuperMix (Invitrogen).
For the ﬁrst case (P1), primers were designed using HCV Los
Alamos Sequence Database: 5′CGCAACCTCGTGGAAGGAAGGC-
GACA3′ (508–529),
5′CGCACGTGAGGAGGATGATGGC3′(2976-2955), 5′GACCT-
CATGGGGTACATTCCGC3′ (735–756), 5′CTCACGATGCAGCCATCTCC-
CGGTCC3′ (2796-2771).
The ﬁrst round of ampliﬁcation began with a denaturation step
at 94 1C for 2 min, followed by 40 cycles of denaturation at 94 1C
for 30 s, primer annealing at 60 1C for 30 s, primer extension at
68 1C for 2 min 40 s, and then a ﬁnal step at 68 1C for 10 min.
Nested PCR began with a denaturation step at 94 1C for 2 min and
was followed by 35 cycles of denaturation at 94 1C for 30 s, primer
annealing at 57 1C for 30 s, primer extension at 68 1C for 2 min
30 s, and a ﬁnal step at 68 1C for 10 min. For the second case (P2),
we used published primers (Brown et al., 2005). An initial step of
denaturation was performed at 94 1C for 2 min. PCR-cycling
parameters were 35 cycles of 94 1C for 30 s, 60 1C for 30 s, 68 1C
for 2 min 20 s, and ﬁnally 68 1C for 10 min. The PCR products were
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clones per sample were sequenced.
Analysis of early genetic evolution of E1 and E2 for patient P2
Evolutionary analyses were performed on patient P2 providing
more information in terms of variation. A ﬁrst step before any
evolutionary analysis is to align sequences from the various virion
variants (time t1 and t2 and an external close reference outgroup
of type 3a – D28917 – used to root the evolutionary tree). This step
allows to account for possible insertions and deletions that may
have occurred and align equivalent codon positions. Single muta-
tions occurring on a given position and affecting several variants
(descendants) may then be identiﬁed. Such alignment methods
make little biological assumptions about the mutational model,
but for different insertion deletion and punctual mutation rates.
Yet the method is robust to such parameters especially for close
sequence as in the present dataset where alignment should be
quite straightforward. We applied MAFFT (Katoh et al., 2005) with
default options. This is a standard and reliable method more
efﬁcient than the more classical Clustalw method.
The next step was to reconstruct an evolutionary (phyloge-
netic) tree representing the history of the variants and associated
mutation events. We applied the most standard reference method:
a probabilistic method providing the tree showing the best ﬁt to
the data, with a maximum likelihood statistical method using
PHYML 2.4 (Guindon et al., 2005). This step relies on assuming a
mutational model. A model selection procedure provided HKY85
mutational model as showing the best ﬁt to the data. This is as
simple mutational model allowing in particular for various fre-
quencies of the four nucleotides and different mutation rates of
transitions and transversions. The signiﬁcance of the branches of
the tree was tested with a randomization, bootstrap test.
Standard population genetics statistics were computed with
the corresponding reference software DNAsp 5.0 (Librado and
Rozas, 2009). We estimated the diversity which corresponds to the
average number of differences per bp between two individual
variants (Nei and Tajima, 1981). We then addressed whether the
two samples t1 and t2 were genetically statistically different. We
computed a genetic distance index between them: genetic differ-
entiation index FST (Hudson et al., 1992a,1992b). This index
corrects for within sample variation and ranges from 0 to 1 with
increasing allele frequency differences. The statistical signiﬁcance
of the FST was assessed empirically by randomization: 1000
permutations of the variants between the two samples (Hudson
et al., 1992a,1992b). Natural selection test were then applied.
Under neutrality, i.e. random mutational evolution in the absence
of functional effect, the ratio of non-synonymous to synonymous
changes is expected to be constant over time. The McDonald and
Kreitman (1991) neutrality test compares this ratio between two
evolutionary scales: within sample variation versus that of ﬁxed
differences with the outgroup strain.
Selective pressure along the E1 and E2 genes on a codon by
codon basis was further studied with methods relying on evolu-
tionary tree (Delport et al., 2009). They are based on the same
comparison of non synonymous to synonymous rates, but com-
pare the corresponding difference to expected values of (i) 0 for
strict neutrality. In contrast (ii) negative values should result from
deleterious changes, when some of the non synonymous changes
are eliminated, which corresponds to the most common case for
coding data. Finally, (iii) positive values are expected when faced
to diversifying positive selection favoring successive replacement
of amino acids on a given codon position (e.g. to counteract
immune system recognition).
However recombination or any form of gene exchange may
largely affect phylogenetic selective analyses: the variousfragments of sequence separated by recombination correspond
to different ancestors, and thus different evolutionary trees.
Recombination should thus be tested prior to such analyses
(Anisimova et al., 2003). We ﬁrst tested qualitatively for recombi-
nation on the whole dataset. Linkage disequilibrium (LD) indices
reﬂect how often mutations at two positions are carried by the
same individual sequences. Such index essentially breaks down
with recombination. The more distant the sites along the
sequence, the more there is opportunity for recombination to
occur between them and the lower the LD value. Thus recombina-
tion predicts a decay of LD with the distance between pairs of
variable sites. The LD indices may be affected by other factors
through mutation frequency effects, but recombination is the only
simple explanation that may account for such decay. This is the
essence of the test we used to detect recombination. We assessed
recombination with such a correlation as tested by random
permutations of sites (Awadalla et al., 1999). Once recombination
is detected, we need to split the sequence alignment according to
putative recombination events and apply the phylogenetic and
associated selective methods separately on the resulting fragments
(Schefﬂer et al., 2006). To assess more precisely putative recombi-
nation positions, we applied Rm method that looks for pairs of sites
with mutation conﬁguration incompatible in the absence of
recombination (Hudson and Kaplan, 1985). Resulting detected
events may alternatively reﬂect multiple mutation hit events
occurring on a given position. But this is a safe way to remove
all recombination effect (and more than that). Two selective
analyses were applied to each of these fragments corresponding
to two statistical recommended ways to estimate the mutation
rates. The FEL procedure was used to detect negative selection by
testing if the non synonymous mutation rate was smaller than the
synonymous one on a codon by codon basis (Kosakovsky Pond and
Frost, 2005)). The related MEME procedure was used to detect
positive selection (diversifying) with an opposite test on a branch
speciﬁc basis thus accounting for episodic selection occurring only
at speciﬁc time on the tree (Kosakovsky Pond et al., 2011).
Site-directed mutagenesis
Two mutants bearing one amino acid substitution (M299V in E1
and N645S in E2) were obtained by site-directed mutagenesis of
the major variant P1t2c16. P1t2c16 DNA was ampliﬁed using two
pairs of non overlapping synthetic primers:(i) CGCTTGCAGTTGGACCAGAG and GCTTCGAACCTGTGCTCCAC
(ii) CGGCACGTGACAGTACAGGA and GCGAGGTGAGAAAGTGAACA.
The resulting PCR products were treated with DpnI endonu-
clease and puriﬁed before ligation using T4 DNA ligase.HCVpp production
Cells and antibodies and plasmids are described as
Supplemental data. Plasmids containing full-length E1and E2
cDNA sequences were digested with EcoRI. The resulting fragment
was inserted into the vector pcDNA3.1(+) (Invitrogen). HCV retro-
viral pseudoparticles (HCVpp) were generated. Brieﬂy, 3.5106
293T cells were seeded into 75 cm2 cell culture ﬂasks. After a 16-h
culture, they were transfected and a plasmid DNA mixture con-
sisting of 4 mg of pcDNA3.1(+) vector coding for the HCV envelope
glycoproteins of HCV variants, 3.8 mg of vector coding for the core
and the packaging components from murine leukemia virus
(pMNGagPol) and 3.8 mg of a murine leukemia virus retroviral
transfer vector harboring a marker gene encoding the Fireﬂy
luciferase (pTG-Luc). Pseudoparticles bearing HCV H77—E1 and
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reference (HCVpp-1a).
Control pseudoparticles bearing MLV envelope proteins were
produced by transfection with pCMVAmpho and used as positive
controls (Ampho), or with pcDNA3.1+ vector (Invitrogen) to be
used as negative controls (dEnv). Pseudoparticles were harvested
48 and 72 h post transfection. 293T cells were washed with PBS,
then treated with lysis buffer. Supernatants were collected after a
12,000g centrifugation for 15 min at 4 1C and stored at 80 1C.
Analysis of HCVpp envelope proteins
Puriﬁed pseudoparticles were obtained by ultracentrifugation of
10 ml of supernatant through a 20 w/v sucrose cushion. Pellets were
resuspended in PBS and mixed with loading buffer. Samples were
treated with 5 v/v beta-mercaptoethanol and preheated at 95 1C for
4 min before electrophoresis. Proteins were transferred to a nitrocel-
lulose membrane. The MLV capsid protein was detected with anti-
MLV capsid antibody, HCV E1 with monoclonal antibodies H-111 or
A4, and HCV E2 with monoclonal antibody 3/11.
In vitro infection experiments with HCVpp
Fireﬂy Luc RNA was assayed by RT-PCR and used to normalize
pseudoparticle-containing supernatants for infectivity experi-
ments. Viral RNA was isolated from 100 ml of supernatant and
digested with DNase. Ten microliter aliquots of RNA extract were
used for reverse transcription. Then, two microliters of cDNA were
used for quantitative PCR using oligonucleotides speciﬁc for the
Fireﬂy Luciferase gene. HCVpp-containing supernatants were
diluted to 2.5.104 copies pTG-Luc RNA ml1 with cell culture
medium. Huh7 cells were seeded in 48-well plates at 20,000 cells
per well and incubated for 16 h. The culture medium was then
removed and 300 ml of supernatants was added in triplicate and
the cultures incubated for 6 h; the medium was then replaced
with complete DMEM. Infection efﬁcacy was evaluated after 72 h
with the luciferase assay. Cells were washed with PBS once and
lyzed with 40 ml per well of lysis buffer. Twenty microliters of
lysate was mixed with 20 ml of luciferin and luciferase activity was
determined by measuring luminescence in a luminometer for 10 s
and is expressed in relative luciferase units (RLU).Serum neutralization assays
Sera were diluted 1:50 in HCVpp-containing supernatants,
incubated for 1 h at 37 1C, and added to Huh7 in 48-well plates
(20,000 cells per well). No signiﬁcant elevation of HDL level was
observed in HCV negative controls and patients sera (HDL levels
under 1 mM l1). In this context, modulation of neutralization
effect by lipids is a minor bias. Each neutralization assay was
performed in triplicate. The negative control (NC) was a pool of
sera from 98 blood donors who tested negative for HCV RNA and
anti-HCV antibody. Two different positive controls were used: a
mixture of four sera (anti-E2 pool) which were anti-HVR1 anti-
body-positive as tested with INNO-LIA HCV Score (Innogenetics);
and a pool of puriﬁed IgGs from three patients infected with a type
3 HCV (IgGt3). Infection of target cells was measured after
incubation of HCVpp with each patient serum or with the negative
control (NC) at the same dilutions. The percentage of antibody-
mediated neutralization was calculated as: 100 (1—serum/nega-
tive control) with values expressed in RLU. Neutralization values
higher than 50% were considered signiﬁcant. For titration of
neutralizing antibodies in case P2, sequential autologous sera (t1
to t8) were serially diluted (1:25, 1:50, 1:100, 1:200 and 1:400)and the dilution causing 50% inhibition of infectivity was
determined.Nucleotides sequences
Nucleotide sequences of HCV E1 and E2 domains were sub-
mitted to GenBank under accession numbers JQ285738 to
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